share_log

Sensus Healthcare, Inc. (NASDAQ:SRTS) CEO Joseph C. Sardano Sells 36,093 Shares

kopsource ·  Aug 12, 2022 07:52

Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Rating) CEO Joseph C. Sardano sold 36,093 shares of the business's stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $13.97, for a total transaction of $504,219.21. Following the completion of the transaction, the chief executive officer now owns 1,294,200 shares in the company, valued at approximately $18,079,974. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Sensus Healthcare Stock Up 0.3 %

Shares of SRTS traded up $0.04 during trading hours on Thursday, reaching $14.09. 257,488 shares of the company traded hands, compared to its average volume of 295,234. The company's fifty day moving average price is $9.51 and its two-hundred day moving average price is $9.23. The company has a market capitalization of $234.99 million, a price-to-earnings ratio of 9.33 and a beta of 0.78. Sensus Healthcare, Inc. has a 12 month low of $3.21 and a 12 month high of $14.82.

Get Sensus Healthcare alerts:

Analyst Ratings Changes

Separately, Maxim Group restated a "buy" rating and issued a $14.00 price objective on shares of Sensus Healthcare in a research report on Friday, May 6th.

Institutional Investors Weigh In On Sensus Healthcare

A number of large investors have recently modified their holdings of the stock. Bailard Inc. boosted its stake in shares of Sensus Healthcare by 3.9% during the 2nd quarter. Bailard Inc. now owns 34,600 shares of the company's stock valued at $266,000 after purchasing an additional 1,300 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Sensus Healthcare by 83.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 5,500 shares of the company's stock valued at $40,000 after purchasing an additional 2,500 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Sensus Healthcare by 15.0% during the 1st quarter. Northern Trust Corp now owns 24,602 shares of the company's stock valued at $249,000 after purchasing an additional 3,203 shares in the last quarter. Sheaff Brock Investment Advisors LLC boosted its stake in shares of Sensus Healthcare by 16.3% during the 1st quarter. Sheaff Brock Investment Advisors LLC now owns 25,264 shares of the company's stock valued at $255,000 after purchasing an additional 3,550 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Sensus Healthcare by 8.9% during the 1st quarter. State Street Corp now owns 46,052 shares of the company's stock valued at $466,000 after purchasing an additional 3,765 shares in the last quarter. Institutional investors own 20.49% of the company's stock.

About Sensus Healthcare

(Get Rating)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Read More

  • Get a free copy of the StockNews.com research report on Sensus Healthcare (SRTS)
  • Why Invest in High-Yield Dividend Stocks?
  • Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
  • Find and Profitably Trade Stocks at 52-Week Lows
  • Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
  • 3 Stable Growth Stocks for Bumpy Times

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment